In an endometriosis rat model, the angiotensin II receptor blocker losartan reduced TGF-β, and the surface area of endometriosis lesions was decreased as were the plasma levels of the angiogenic factors and inflammatory markers VEGF, TNF-α, PTX-3, and CRP [39,40]. The gene discussed is CRP; the disease is endometriosis.